Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT00001823	TitleEvaluation for NCI Surgery Branch Immunotherapy Clinical Research Protocols	Fase	Date Added 1999-11-04	Ubicación Maryland, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05482516	TitleEvaluating Novel Therapies in ctDNA Positive GI Cancers	Fase Fase 3	Date Added 2022-08-01	Ubicación District of Columbia, United States New Jersey, United States	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Atezolizumab, Bevacizumab, Avastin, Tecentriq	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06060704	TitleEnvafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.	Fase Fase 2	Date Added 2023-09-29	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Bevacizumab, Envafolimab, Trifluridine/Tipiracil, Avastin, Lonsurf	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT02453620	TitleEntinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer	Fase Fase 1	Date Added 2015-05-25	Ubicación California, United States Connecticut, United States Maryland, United States Pennsylvania, United States	Prior IO Allowed Sí	CRC-directed No	Status Activo, no recluta	Drogas Entinostat, Ipilimumab, Nivolumab, Opdivo, Yervoy	Etiquetas MSS/ MMRp
NCT ID NCT04017650	TitleEncorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer	Fase Phase 1, Phase 2	Date Added 2019-07-12	Ubicación Texas, United States	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas cetuximab, encorafenib, Nivolumab	Etiquetas MSS/ MMRp
NCT ID NCT06923761	TitleEMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial – 1)	Fase Fase 1	Date Added 2025-04-11	Ubicación Australia Francia España Reino Unido	Prior IO Allowed Sí	CRC-directed No	Status Reclutamiento	Drogas	Etiquetas MSI-H/ MMRd
NCT ID NCT04853017	TitleELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201)	Fase Fase 1	Date Added 2021-04-21	Ubicación California, United States Colorado, United States Iowa, United States Massachusetts, United States Missouri, United States New York, United States Tennessee, United States Texas, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04730544	TitleEfficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer ( NIPISAFE )	Fase Fase 2	Date Added 2021-01-29	Ubicación Francia	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Ipilimumab, Nivolumab	Etiquetas MSI-H/ MMRd
NCT ID NCT06008119	TitleEfficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer	Fase Fase 3	Date Added 2023-08-23	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab, Tunlametinib plus Vemurafenib	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05799443	TitleEfficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer	Fase Fase 2	Date Added 2023-04-05	Ubicación	Prior IO Allowed Sí	CRC-directed Sí	Status Aún no se ha contratado	Drogas cetuximab, Irinotecan Hydrochloride, Tislelizumab	Etiquetas MSI-H/ MMRd, MSS/ MMRp

Showing 171 to 180 of 299 entries